BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 21133669)

  • 1. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.
    Almyroudis NG; Segal BH
    Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1451-66. PubMed ID: 21133669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
    Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR
    Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies.
    Marr KA
    Curr Opin Infect Dis; 2008 Aug; 21(4):409-14. PubMed ID: 18594294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.
    McCoy D; Depestel DD; Carver PL
    Pharmacotherapy; 2009 Nov; 29(11):1306-25. PubMed ID: 19857148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
    Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
    Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies.
    Leather HL; Wingard JR
    Blood Rev; 2006 Sep; 20(5):267-87. PubMed ID: 16781028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
    Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
    Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing strategies for the management of invasive fungal infections.
    Rapp RP
    Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
    Maertens J
    Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer antifungal agents for invasive fungal infections in patients with haematological malignancy.
    Rogers TR; Frost S
    Br J Haematol; 2009 Mar; 144(5):629-41. PubMed ID: 19120371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
    Ziakas PD; Kourbeti IS; Mylonakis E
    Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal prophylaxis and treatment in patients with hematological malignancies.
    Hwang YY; Liang R
    Expert Rev Anti Infect Ther; 2010 Apr; 8(4):397-404. PubMed ID: 20377335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation.
    Michallet M; Ito JI
    J Clin Oncol; 2009 Jul; 27(20):3398-409. PubMed ID: 19487382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success.
    Kontoyiannis DP
    Bone Marrow Transplant; 2011 Feb; 46(2):165-73. PubMed ID: 21042306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal treatment in patients with cancer.
    Viscoli C; Castagnola E; Machetti M
    J Intern Med Suppl; 1997; 740():89-94. PubMed ID: 9350188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.
    Bow EJ; Laverdière M; Lussier N; Rotstein C; Cheang MS; Ioannou S
    Cancer; 2002 Jun; 94(12):3230-46. PubMed ID: 12115356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current role of amphotericin B lipid complex in managing systemic fungal infections.
    Chu P; Sadullah S
    Curr Med Res Opin; 2009 Dec; 25(12):3011-20. PubMed ID: 19849324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
    Glasmacher A; Prentice AG
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal therapy strategies in hematopoietic stem-cell transplant recipients: early treatment options for improving outcomes.
    Chandrasekar P; Ljungman PT
    Transplantation; 2008 Jul; 86(2):183-91. PubMed ID: 18645475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
    Sohn HS; Lee TJ; Kim J; Kim D
    Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.